The era of personalized medicine for cancer therapeutics has taken an important step forward in making accurate prognoses for individual patients with the adoption of high-throughput microarray technology. However, microarray technology in cancer diagnosis or prognosis has been primarily used for the statistical evaluation of patient populations, and thus excludes inter-individual variability and patient-specific predictions. Here we propose a metric called clinical confidence that serves as a measure of prognostic reliability to facilitate the shift from population-wide to personalized cancer prognosis using microarray-based predictive models. The performance of sample-based models predicted with different clinical confidences was evaluated and compared systematically using three large clinical datasets studying the following cancers: breast cancer, multiple myeloma, and neuroblastoma. Survival curves for patients, with different confidences, were also delineated. The results show that the clinical confidence metric separates patients with different prediction accuracies and survival times. Samples with high clinical confidence were likely to have accurate prognoses from predictive models. Moreover, patients with high clinical confidence would be expected to live for a notably longer or shorter time if their prognosis was good or grim based on the models, respectively. We conclude that clinical confidence could serve as a beneficial metric for personalized cancer prognosis prediction utilizing microarrays. Ascribing a confidence level to prognosis with the clinical confidence metric provides the clinician an objective, personalized basis for decisions, such as choosing the severity of the treatment.
References
[1]
Loscalzo J, Kohane I, Barabasi AL (2007) Human disease classification in the postgenomic era: A complex systems approach to human pathobiology. Mol Syst Biol 3: 124.
[2]
Holmes E, Wilson ID, Nicholson JK (2008) Metabolic phenotyping in health and disease. Cell 134: 714–717.
[3]
Abrahams E (2009) Personalized Medicine Realizing Its Promise. Genet Eng Biotechnol News 29(15). Available: http://www.genengnews.com/gen-articles/p？ersonalized-medicine-realizing-its-promi？se/3025/. Accessed: 2012 Jan 2.
[4]
van't Veer LJ, Dai HY, van de Vijver MJ, He YDD, Hart AAM, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–536.
[5]
van de Vijver MJ, He YD, van 't Veer LJ, Dai H, Hart AAM, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999–2009.
[6]
Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, et al. (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22: 2284–2293.
[7]
Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, et al. (2005) Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23: 422–431.
[8]
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869–10874.
[9]
Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393–10398.
[10]
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418–8423.
[11]
Bertucci F, Finetti P, Cervera N, Maraninchi D, Viens P, et al. (2006) Gene expression profiling and clinical outcome in breast cancer. OMICS 10: 429–443.
[12]
Balleine RL, Webster LR, Davis S, Salisbury EL, Palazzo JP, et al. (2008) Molecular Grading of Ductal Carcinoma In situ of the Breast. Clin Cancer Res 14: 8244–8252.
[13]
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752.
[14]
Slodkowska EA, Ross JS (2009) MammaPrint (TM) 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn 9: 417–422.
[15]
Roepman P, Wessels LFA, Kettelarij N, Kemmeren P, Miles AJ, et al. (2005) An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 37: 182–186.
[16]
Williams PD, Cheon S, Havaleshko DM, Jeong H, Cheng F, et al. (2009) Concordant Gene Expression Signatures Predict Clinical Outcomes of Cancer Patients Undergoing Systemic Therapy. Cancer Res 69: 8302–8309.
[17]
Shao L, Wu LH, Fang H, Tong WD, Fan XH (2010) Does applicability domain exist in microarray-based genomic research? PLoS ONE 5: e11055.
[18]
Simon R, Radmacher MD, Dobbin K, McShane LM (2003) Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95: 14–18.
[19]
The MicroArray Quality Control Consortium (2010) The MAQC-II Project: A comprehensive study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 28: 827–838.
[20]
Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, et al. (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24: 4236–4244.
[21]
Shaughnessy JD, Zhan FH, Burington BE, Huang YS, Colla S, et al. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109: 2276–2284.
[22]
Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, et al. (2006) Customized oligonucleotide microarray gene expression based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 24: 5070–5078.
[23]
Theodoridis S, Koutroumbas K (2006) Pattern Recognition. San Diego, CA: Elsevier.
[24]
Matthews BW (1975) Comparison of predicted and observed secondary structure of T4 phage lysozyme. Biochim Biophys Acta 405: 442–451.
[25]
Baldi P, Brunak S, Chauvin Y, Andersen CAF, Nielsen H (2000) Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics 16: 412–424.
[26]
Radmacher MD, McShane LM, Simon R (2002) A paradigm for class prediction using gene expression profiles. J Comput Biol 9: 505–511.
[27]
Fan XH, Shi LM, Fang H, Cheng YY, Perkins R, et al. (2010) DNA microarrays are predictive of cancer prognosis: A re-evaluation. Clin Cancer Res 16: 629–636.
[28]
Cohen J (1992) A power primer. Psychol Bull 112: 155–159.
[29]
Ely S (2009) Personalized medicine: individualized care of cancer patients. Trans Res 154: 303–308.
[30]
Cantor MN (2009) Enabling personalized medicine through the use of healthcare information technology. Per Med 6: 589–594.
